IA
JANX icon

IFP Advisors’s Janux Therapeutics JANX Stock Holding History

IFP Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15 Sell
1
-1
-50% -$14 ﹤0.01% 5083
2026
Q1 		$28 Buy
+2
New +$27 ﹤0.01% 4896
2025
Q4 		– Sell
-50
Closed -$1.22K – 4968
2025
Q3 		$1.22K Sell
50
-6
-11% -$146 ﹤0.01% 3874
2025
Q2 		$1.29K Buy
56
+55
+5,500% +$1.45K ﹤0.01% 4109
2025
Q1 		$27 Hold
1
– – ﹤0.01% 4131
2024
Q4 		$54 Buy
+1
New +$53 ﹤0.01% 4237

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

IFP Advisors's JANX Position: Q2 2026 in Review

IFP Advisors reduced its Janux Therapeutics (JANX) stake by 50% in Q2 2026, selling an estimated $14 and leaving 1 share worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #5083.

IFP Advisors first reported a position in JANX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.29K in Q2 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • IFP Advisors held 1 share of Janux Therapeutics worth $15 as of Q2 2026.
  • IFP Advisors sold 1 Janux Therapeutics share in Q2 2026, an estimated $14.
  • Janux Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5083 holding.
  • IFP Advisors first reported a position in Janux Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • IFP Advisors's Janux Therapeutics position peaked at $1.29K in Q2 2025.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.